PMID- 35931835
OWN - NLM
STAT- MEDLINE
DCOM- 20230127
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 2
DP  - 2023 Feb
TI  - Low-dose anlotinib confers improved survival in combination with immune 
      checkpoint inhibitor in advanced non-small cell lung cancer patients.
PG  - 437-448
LID - 10.1007/s00262-022-03259-5 [doi]
AB  - BACKGROUND: Anti-angiogenic drugs increase anti-tumor efficacy of immune 
      checkpoint inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs 
      remains unclear. METHODS: We retrospectively analyzed efficacy and safety data 
      from patients diagnosed with advanced or metastatic non-small cell lung cancer 
      (NSCLC) that received PD-1 blockade with low-doses of anlotinib, a highly 
      selective receptor tyrosine kinase inhibitor mainly targeting vascular 
      endothelial growth factor receptors, as second or later line therapy. The primary 
      endpoint was progression-free survival (PFS). Secondary endpoints included 
      overall survival (OS), overall response rate (ORR), disease control rate (DCR), 
      and safety profile. Univariate and multivariate analyses were used to identify 
      prognostic factors. RESULTS: A total of 40 eligible patients were included. The 
      median PFS was 11.4 months. The median OS of the entire cohort was 27.0 months. 
      ORR was achieved in 16 patients (40.0%) and DCR was maintained in 33 patients 
      (82.5%). The overall incidence of adverse events (AEs) was 52.5%, and the most 
      common all grade AE was gastrointestinal reactions, which occurred in four 
      patients (10.0%). Treatment-related grade 3/4 toxicity was observed in one 
      patient (2.5%). Conclusions Low-dose anlotinib may be an effective and 
      well-tolerated anti-angiogenesis partner for combination therapy with ICIs in 
      second-line and later settings for advanced NSCLC.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yuan, Shumin
AU  - Yuan S
AD  - Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Peng, Ling
AU  - Peng L
AD  - Department of Respiratory Disease, Zhejiang Provincial People's Hospital, 
      Hangzhou, China.
FAU - Liu, Yuqing
AU  - Liu Y
AD  - Department of Medical Oncology, Third Affiliated Hospital of Xinxiang Medical 
      University, Xinxiang, China.
FAU - Till, Brian G
AU  - Till BG
AD  - Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United 
      States.
FAU - Yan, Xiang
AU  - Yan X
AD  - Medical Oncology Department, The Chinese PLA General Hospital, Beijing, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Medical Oncology Department, The Chinese PLA General Hospital, Beijing, China.
FAU - Zhu, Liping
AU  - Zhu L
AD  - Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical 
      University, Xinxiang, China.
FAU - Wang, Huijuan
AU  - Wang H
AD  - Department of Medical Oncology, Shouguang Hospital of Traditional Chinese 
      Medicine, Shouguang, China.
FAU - Zhang, Shaokai
AU  - Zhang S
AD  - Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, 
      The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Li, Hongle
AU  - Li H
AD  - Molecular Pathology Department, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China. llhl73@163.com.
FAU - Gao, Quanli
AU  - Gao Q
AD  - Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China. zlyygql0855@zzu.edu.cn.
FAU - Wang, Zibing
AU  - Wang Z
AUID- ORCID: 0000-0002-6882-145X
AD  - Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China. zlyywzb2118@zzu.edu.cn.
LA  - eng
GR  - 81972690/National Natural Science Foundation of China/
GR  - 81000914/National Natural Science Foundation of China/
GR  - YXKC2021007/Medical Science and Technology Research Project of Health Commission 
      of Henan Province/
GR  - SBGJ202101008/Medical Science and Technology Research Project of Health 
      Commission of Henan Province/
PT  - Journal Article
DEP - 20220805
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (anlotinib)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Quinolines)
RN  - 0 (Indoles)
SB  - IM
MH  - Humans
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Immune Checkpoint Inhibitors/therapeutic use
MH  - *Lung Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - *Quinolines/therapeutic use
MH  - Indoles/therapeutic use
PMC - PMC10991614
OTO - NOTNLM
OT  - Anti-angiogenic drugs
OT  - Combination therapy
OT  - ICIs
OT  - NSCLC
OT  - Second-line treatment
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/08/06 06:00
MHDA- 2023/01/26 06:00
PMCR- 2022/08/05
CRDT- 2022/08/05 23:26
PHST- 2022/01/04 00:00 [received]
PHST- 2022/07/11 00:00 [accepted]
PHST- 2022/08/06 06:00 [pubmed]
PHST- 2023/01/26 06:00 [medline]
PHST- 2022/08/05 23:26 [entrez]
PHST- 2022/08/05 00:00 [pmc-release]
AID - 10.1007/s00262-022-03259-5 [pii]
AID - 3259 [pii]
AID - 10.1007/s00262-022-03259-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Feb;72(2):437-448. doi: 
      10.1007/s00262-022-03259-5. Epub 2022 Aug 5.